

NMI TT Pharmaservices

Our new Cav1.2 cell line

AGAMI technology

Product information

Host cell: CHO-K1
Platforms: Fluorescence, QPatch,
Tested reference inhibitors: Nifedipine, Verapamil, Isradipine
Tested reference activators: FPL64176

Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension. Due to their key role in shaping the cardiac action potential, they are part of the CiPA-compliant panel of human ion channel to be tested for cardiac safety.

Key features of our Cav1.2 cell line:

- stable expression of all three subunits of the native Cav1.2 channel (α1c/β2/α2δ)
- high success rates and reliable performance in automated patch clamp assays, using Sophion and Nanion platform
- Run-down free recordings
- Inducible system: easy to maintain in cell culture, adjustable expression level

QPatch: Cav1.2 dose response data



QPatch: Cav1.2 blocked by nifedipine



Stable, run-down free recordings



Effect of FPL64176 on Cav1.2 currents



NMI TT Pharmaservices
Markwiesenstraße 55
72770 Reutlingen,
Germany
Phone +49 7121 51530-0
Fax +49 7121 51530-16
www.nmi-tt.de

Contact
Dr. Timm Danker
Phone +49 7121 51530-896
danker@nmi-tt.de
Dr. Udo Kraushaar
Phone +49 7121 51530-851
kraushaar@nmi-tt.de

www.nmi-tt.de/cav1.2